论文信息 - Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.

Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.

1. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127. 2. Lester JF, Macbeth FR, Brewster AE, et al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer. 2004;45:237–242. 3. Soliman H, Cheung P, Yeung L, et al. Accelerated hypofractionated radiotherapy for early-stage non–small-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys. 2011;79:459–465.

Yongling Xiao | P. Lefebvre | D. Pilon | L. Ellis | A. Behl

[1] D. Thompson,et al. Optimizing Chemotherapy: Concomitant Medication Lists , 2010, Clinical pharmacology and therapeutics.

[2] F. Saad,et al. Guidelines for the management of castrate-resistant prostate cancer , 2010 .

[3] R. Riechelmann,et al. Drug interactions in oncology: how common are they? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4] D. Olmos,et al. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer , 2009, British Journal of Cancer.

[5] C. Ling,et al. Results of a phase I dose‐escalation study using three‐dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma , 2005, Cancer.

[6] J. Lester,et al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. , 2004, Lung cancer.

[7] T Welte,et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. , 2000, International journal of clinical pharmacology and therapeutics.